drugset
drugset / Trial / NCT04523792

Virginia Opioid Treatment-Emergency Department

NCT04523792 ↗

Phase 3 Withdrawn Virginia Commonwealth University Indivior Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The current study seeks to test the feasibility of an alternative treatment for patients with opioid use disorder who present to the emergency department seeking treatment or with opioid withdrawal, which includes FDA approved long-acting medication for opioid misuse (SUBLOCADE) and rapid transfer of care to outpatient substance abuse treatment.

Timeline

Start
2021-01-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 100 mg Subcutaneous
Subject Buprenorphine Other / unclassified 300 mg Subcutaneous

Indications

opiate dependence